Interpace Biosciences

Interpace Biosciences Goodwill

The Goodwill of Interpace Biosciences (IDXG) as of Oct 30, 2026 is 8.43 M USD. In the previous year, Goodwill was 8.43 M USD — a change of 0.00% (lower).

Goodwill

8.43 MUSD

YoY

0.00%

Last updated:

Goodwill of Interpace Biosciences is 2021 8.43 M USD. Goodwill of Interpace Biosciences was 2020 8.43 M USD. It decreases by 0.00% lower compared to the previous year.

The Interpace Biosciences Goodwill history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Goodwill
Date
Goodwill
Jan 1, 2014
15.55 M USD
Jan 1, 2015
0.00 USD
Jan 1, 2016
0.00 USD
Jan 1, 2017
0.00 USD
Jan 1, 2019
8.43 M USD
Jan 1, 2020
8.43 M USD
Jan 1, 2021
8.43 M USD
The Interpace Biosciences Goodwill history
YEARGoodwillYoY
8.43 MUSD0.00%
8.43 MUSD0.00%
8.43 MUSD—
0.00USD—
0.00USD—
0.00USD-100.00%
15.55 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Interpace Biosciences Stock analysis

What does Interpace Biosciences do? Interpace Biosciences develops and sells diagnostic clinical and pharma services, focusing on molecular tests for cancer risk evaluation. The company offers five commercialized tests: PancraGEN for pancreatic cancer diagnosis from cysts, PanDNA as a molecular snapshot of limited factors, ThyGeNEXT for thyroid cancer diagnosis using sequencing, ThyraMIR v2 used with ThyGeNEXT for thyroid cancer, and RespriDX to differentiate lung cancer origins. These products are sold to healthcare providers and laboratories seeking advanced diagnostic solutions for cancer risk assessment and treatment planning. Interpace Diagnostics, the company's division, provides bioinformatics and pathology services alongside its molecular tests. The tests target specific cancer types, with PancraGEN and PanDNA addressing pancreatic cancer, ThyGeNEXT and ThyraMIR v2 for thyroid cancer, and RespriDX for lung cancer differentiation. Healthcare institutions and physicians utilize these services to improve diagnostic accuracy and patient outcomes in oncology care. The company's revenue streams come from the direct sale of its molecular diagnostic tests and associated services to medical professionals and healthcare facilities. These services are positioned for precision medicine applications, supporting cancer diagnosis, prognosis, and treatment decisions. The business model relies on the clinical utility and technological innovation of its tests to drive adoption among healthcare providers focused on oncology diagnostics. Interpace Biosciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Interpace Biosciences stock

Goodwill of Interpace Biosciences is 8.43 M USD in 2021.

Goodwill of Interpace Biosciences changed from 8.43 M USD to 8.43 M USD, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Goodwill Interpace Biosciences since 2006 – with annual values, charts, and detailed analysis.

Goodwill is the premium paid above fair market value in an acquisition. It represents intangible value such as brand recognition, customer relationships, and intellectual property.

Goodwill's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill's Interpace Biosciences historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Interpace Biosciences

All Key Metrics — Interpace Biosciences